VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.2500
-0.0020 (-0.79%)
At close: Dec 26, 2025, 4:00 PM EST
0.2573
+0.0073 (2.92%)
After-hours: Dec 26, 2025, 8:00 PM EST
VolitionRx Revenue
VolitionRx had revenue of $406.69K in the quarter ending June 30, 2025, with 2.75% growth. This brings the company's revenue in the last twelve months to $1.32M, up 35.10% year-over-year. In the year 2024, VolitionRx had annual revenue of $1.23M with 59.10% growth.
Revenue (ttm)
$1.32M
Revenue Growth
+35.10%
P/S Ratio
16.98
Revenue / Employee
$17,318
Employees
85
Market Cap
30.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
| Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
| Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
| Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
| Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
| Dec 31, 2019 | 17.10K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 54.97K | - | - |
| Dec 31, 2011 | - | - | - |
| Aug 31, 2011 | - | - | - |
| Aug 31, 2010 | - | - | - |
| Aug 31, 2009 | - | - | - |
| Aug 31, 2008 | - | - | - |
| Aug 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VNRX News
- 10 days ago - Volition Issues Business Review 2025 - PRNewsWire
- 16 days ago - Volition Solves Liquid Biopsy's "Needle in a Haystack" Problem; Achieves 180-fold (18,000%) Enrichment - PRNewsWire
- 19 days ago - Volition Announces Two Abstracts were Presented at the North America Conference on Lung Cancer - PRNewsWire
- 23 days ago - VolitionRx Limited Announces Inclusion of its Nu.Q® NETs Assay as Innovative Biomarker in France's Real-World Evaluation of Early Detection of Sepsis - PRNewsWire
- 4 weeks ago - VolitionRx Limited Announces the First Sale of the Nu.Q® Cancer Assays for Clinical Certification in Preparation for Routine Clinical Use - PRNewsWire
- 6 weeks ago - VolitionRx Limited (VNRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - VolitionRx Limited Announces Third Quarter 2025 Financial Results and Business Update - PRNewsWire
- 6 weeks ago - VolitionRx Limited Schedules Third Quarter 2025 Earnings Conference Call and Business Update - PRNewsWire